Millipore Sigma Vibrant Logo

100050 1400W - CAS 214358-33-5 - Calbiochem

A selective, cell-permeable, irreversible, slow, tight-binding inhibitor of inducible nitric oxide synthase (iNOS; Kd = 7 nM).

1400W - CAS 214358-33-5 - Calbiochem : FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.

Synonymes: N-(3-Aminomethyl)benzylacetamidine, 2HCl

Primary Target: iNOS
View Products on Sigmaaldrich.com
100050
Voir les Prix & la Disponibilité

Aperçu

Replacement Information

Tableau de caractéristiques principal

CAS #Empirical Formula
214358-33-5C₁₀H₁₅N₃ · 2HCl

Prix & Disponibilité

Référence DisponibilitéConditionnement Qté Prix Quantité
100050-5MG
Récupération des données relatives à la disponibilité...
—
Disponibilité limitée Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

      		 Ampoule plast. 5 mg
      Prix en cours de récupération
      Le prix n'a pas pu être récupéré
      La quantité minimale doit être un multiple de
      Maximum Quantity is
      À la validation de la commande Plus d'informations
      Vous avez sauvegardé ()
       
      —
      Demander le prix
      		 —
      Description
      OverviewA selective, cell-permeable, irreversible, slow, tight-binding inhibitor of inducible nitric oxide synthase (iNOS; Kd = 7 nM). Suitable for use in both in vitro and in vivo systems. Has a protective effect against cerebral ischemia by reducing ischemic lesion volumes. Exhibits greater than 5000- and 200-fold potency against human iNOS relative to eNOS and nNOS, respectively, and greater than 1000-fold potency against rat iNOS relative to eNOS.
      Catalogue Number100050
      Brand Family Calbiochem®
      SynonymsN-(3-Aminomethyl)benzylacetamidine, 2HCl
      References
      ReferencesParmentier, S., et al. 1999. Br. J. Pharmacol. 127, 546.
      Cardenas, A., et al. 1998. Eur. J. Pharmacol. 354, 161.
      Parrino, P.E., et al. 1998. Ann. Thorac. Surg. 66, 733.
      Garvey, E.P., et al. 1997. J. Biol. Chem. 272, 4959.
      Laszlo, F., and Whittle, B.J. 1997. Eur. J. Pharmacol. 334, 99.
      Thomsen, L.L., et al. 1997. Cancer Res. 57, 3300.
      Product Information
      CAS number214358-33-5
      ATP CompetitiveN
      FormWhite solid
      Hill FormulaC₁₀H₁₅N₃ · 2HCl
      Chemical formulaC₁₀H₁₅N₃ · 2HCl
      Hygroscopic Hygroscopic
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetiNOS
      Primary Target IC<sub>50</sub>Kd = 7 nM against inducible nitric oxide synthase (iNOS)
      Purity≥95% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage -20°C
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      100050-5MG 04055977226867

      Documentation

      1400W - CAS 214358-33-5 - Calbiochem FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      1400W - CAS 214358-33-5 - Calbiochem Certificats d'analyse

      TitreNuméro de lot
      100050

      Références bibliographiques

      Aperçu de la référence bibliographique
      Parmentier, S., et al. 1999. Br. J. Pharmacol. 127, 546.
      Cardenas, A., et al. 1998. Eur. J. Pharmacol. 354, 161.
      Parrino, P.E., et al. 1998. Ann. Thorac. Surg. 66, 733.
      Garvey, E.P., et al. 1997. J. Biol. Chem. 272, 4959.
      Laszlo, F., and Whittle, B.J. 1997. Eur. J. Pharmacol. 334, 99.
      Thomsen, L.L., et al. 1997. Cancer Res. 57, 3300.

      Brochure

      Titre
      Pathways and Biomarkers of Oxidative Stress

      Citations

      Titre
    • Peyssonnaux, C., et al. 2005. The Journal of Clinical Investigation 115, 1860.
      		•
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision04-April-2011 RFH
      SynonymsN-(3-Aminomethyl)benzylacetamidine, 2HCl
      DescriptionA selective, irreversible, slow, tight binding inhibitor of inducible nitric oxide synthase (iNOS, Kd = 7 nM) both in vitro and in vivo. Has a protective effect against cerebral ischemia by reducing ischemic lesion volumes. Exhibits greater than 5000- and 200-fold potency against human iNOS relative to eNOS and nNOS, respectively, and greater than 1000-fold potency against rat iNOS relative to eNOS.
      FormWhite solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number214358-33-5
      Chemical formulaC₁₀H₁₅N₃ · 2HCl
      Structure formulaStructure formula
      Purity≥95% by HPLC
      SolubilityMethanol (5 mg/ml) or H₂O (1 mg/ml)
      Storage -20°C
      Hygroscopic
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesParmentier, S., et al. 1999. Br. J. Pharmacol. 127, 546.
      Cardenas, A., et al. 1998. Eur. J. Pharmacol. 354, 161.
      Parrino, P.E., et al. 1998. Ann. Thorac. Surg. 66, 733.
      Garvey, E.P., et al. 1997. J. Biol. Chem. 272, 4959.
      Laszlo, F., and Whittle, B.J. 1997. Eur. J. Pharmacol. 334, 99.
      Thomsen, L.L., et al. 1997. Cancer Res. 57, 3300.
      Citation
    • Peyssonnaux, C., et al. 2005. The Journal of Clinical Investigation 115, 1860.
      		•